Kairos Pharma entered into an Investigator/Institution Initiated Research Support Agreement with Bayer to obtain radium for a study evaluating radium with ENV-105 (carotuximab) in models of prostate cancer bone metastasis. Kairos will initiate, manage, and finance the study, and must secure Bayer's written approval before making material protocol changes. The company will deliver final analysis, interpretation, and conclusions to Bayer within six months after the study's completion. The agreement includes customary covenants and confidentiality provisions.
Agreement details:
- Agreement type: Investigator/Institution Initiated Research Support Agreement (radium supply for study)
- Counterparty: Bayer
- Signed / Effective: Jul 16 2026 / same
- Duration / Termination: At will
- Reason: Advance prostate cancer bone metastasis research with radium and ENV-105
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.